Boston Scientific (BSX) Long-Term Investments (2019 - 2026)

Boston Scientific (BSX) posted quarterly Long-Term Investments of $2.2 billion for Q2 2026, up 229.66% on a QoQ basis from $681.0 million in Q4 2025.

Boston Scientific (BSX) Long-Term Investments (2019 - 2026) Analysis & Trends

Boston Scientific has reported Long-Term Investments for 4 years, with the latest figure at $2.2 billion in Q2 2026.

Long-Term Investments for Q2 2026 came in at $2.2 billion, changed N/A year-over-year; the trailing twelve-month figure through Jun 2026 was $2.2 billion (changed N/A YoY), and the FY2025 annual result was $681.0 million, changed N/A from the prior year.
Long-Term Investments grew to $2.2 billion in Q2 2026, from $681.0 million in the prior quarter.
Over five years, Long-Term Investments peaked at $2.2 billion in Q2 2026 and troughed at $681.0 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Abbott Laboratories	202.72 Bn	197.12 Bn	7.27 Bn	1.11 Bn
2	Stryker	126.42 Bn	122.94 Bn	4.50 Bn	-
3	Medtronic	119.75 Bn	110.53 Bn	6.41 Bn	-
4	Boston Scientific	74.13 Bn	73.60 Bn	3.85 Bn	2.25 Bn
5	Edwards Lifesciences	51.78 Bn	47.53 Bn	1.35 Bn	244.10 Mn
6	Dexcom	35.29 Bn	33.34 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.95 Bn	31.85 Bn	2.18 Bn	-
8	Koninklijke Philips	26.22 Bn	22.90 Bn	4.55 Bn	175.52 Mn
9	Steris	23.21 Bn	22.73 Bn	684.20 Mn	-
10	Zimmer Biomet Holdings	19.42 Bn	19.01 Bn	1.54 Bn	-

Download Data